Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 25, 2026, serves as a notice regarding the upcoming Annual General Meeting (AGM) for the 2026 fiscal year. The company is a global biopharma entity headquartered in London, United Kingdom.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural announcement and does not contain financial performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The document focuses solely on corporate governance procedures.
Guidance, Outlook, and Risks
Management Commentary: The Company Secretary, V A Whyte, confirmed the publication of the 2026 AGM Notice, Proxy Form, and marked-up Articles of Association showing proposed changes. These documents are available for inspection via the UK Financial Conduct Authority (FCA) National Storage Mechanism.
Meeting Details: The AGM is scheduled for Wednesday, May 6, 2026, at 2:30 pm at the London Marriott Hotel Grosvenor Square. The meeting will be broadcast live for electronic participation.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the "Risk factors" section of the 2025 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Verify the date and location of the 2026 AGM: May 6, 2026, London Marriott Hotel Grosvenor Square.
- Review the proposed changes to the Articles of Association available on the FCA website.
- Confirm the availability of the Proxy Form and AGM Guide on the GSK investor relations website.
- Note that this filing contains no financial results; refer to the 2025 Form 20-F for the latest financial data.